Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618 → Ser mutation responsive to immune tolerance induction and cyclophosphamide

British Journal of Haematology

Volumn 117, Issue 1, 2002, Pages 136-140

  Vlot, André J ^a,b,d   Wittebol, Shulamiet ^a   Strengers, Paul F W ^c   Turenhout, Ellen A M ^c   Voorberg, Jan ^c   Van Den Berg, H Marijke ^b   Mauser Bunschoten, Eveline P ^b  

^a EEMLAND HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cyclophosphamide; Factor VIII; Factor VIII inhibitors; Haemophilia A; Immune tolerance therapy

Indexed keywords

ARGININE; ASPARAGINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN LIGHT CHAIN; ISOLEUCINE; SERINE; VON WILLEBRAND FACTOR;

ARTICLE; BINDING SITE; BLEEDING; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPRECIPITATION; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; SCREENING TEST;

AGED; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; EPITOPE MAPPING; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MUTATION, MISSENSE; PRECIPITIN TESTS;

EID: 0036227304     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03383.x     Document Type: Article

References (23)

1. Immune tolerance induction and the treatment of hemophilia. Malmo protocol update
2. 593 → Cys substitution
3. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain
4. Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single-stranded conformation polymorphism
5. 593 → Cys is related to antibody formation in a patient with mild hemophilia A
6. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain
7. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies
8. Factor VIII inhibitors in mild and moderate-severity haemophilia A
9. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII
10. A more uniform measurement of factor VIII inhibitors
11. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A
12. The haemophilias -from Royal genes to gene therapy
13. Low-dose immune tolerance induction in hemophilia A patients with inhibitors
14. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII
15. Anti-factor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A
16. 618 → Ser explains cross-reacting material-reduced haemophilia A
17. Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterisation and response to factor VIII and desmopressin
18. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients
19. Haemophilia A: Mutation type determines risk of inhibitor formation
20. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg 593 to Cys Mutation
21. Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene
22. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: Improved specificity and reliability
23. Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid